ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years
Matthew B. Lipner
Matched on ORCID iD 0000-0002-4256-7107; OpenAlex author ID A5079220910; NIH RePORTER profile ID 11508577. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 10
2016: 1 paper · 2017: none · 2018: none · 2019: 1 grant · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 3
- Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. Co-author DOI 10.7717/peerj.17797↗
- Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Co-author DOI 10.1172/jci.insight.129905↗
- Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. Co-author DOI 10.1371/journal.pone.0147113↗
Grants 1
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jen Jen Yeh · 3 shared papers, 2016–2024 · strength 0.36
- Paper Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. DOI 10.7717/peerj.17797↗
- Paper Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. DOI 10.1172/jci.insight.129905↗
- Paper Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. DOI 10.1371/journal.pone.0147113↗
- Gary L. Johnson · 2 shared papers, 2020–2024 · strength 0.30
- Naim U. Rashid · 2 shared papers, 2020–2024 · strength 0.30
- Matthew E. Berginski · 1 shared paper, 2024 · strength 0.20
- Shawn M. Gomez · 1 shared paper, 2024 · strength 0.20
- Yi Xu · 1 shared paper, 2020 · strength 0.09
- Richard A. Moffitt · 1 shared paper, 2020 · strength 0.09
- Lee M. Graves · 1 shared paper, 2020 · strength 0.09
- Cyrus Vaziri · 1 shared paper, 2020 · strength 0.09
- Bert H. O’Neil · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.